Becton, Dickinson and Company (NYSE: BDX) saw its shares advance 3.8% to $177.22 in late-morning trading on Thursday, following the release of fiscal third-quarter results that exceeded analyst expectations. The medical technology company also nudged up its full-year adjusted earnings guidance, citing robust operational performance across its business segments.
The earnings beat was modest, but the improvement in cash generation was substantial. For the nine-month period, free cash flow jumped 44.6% to $1.73 billion, even as adjusted diluted earnings per share slipped 0.7%. The surge was driven primarily by a $564 million reduction in working-capital outflows and other items, which more than accounted for the overall boost in free cash flow. This makes fourth-quarter cash conversion a key metric for investors to watch.
In the fiscal third quarter, revenue came in at $4.983 billion, surpassing the consensus estimate of $4.89 billion and representing a 5.4% year-over-year increase. Adjusted diluted EPS of $3.23 also beat expectations by $0.09, up 4.9% from the prior-year quarter. Chief Executive Tom Polen noted that revenue, adjusted operating margin, and adjusted EPS all exceeded internal projections, calling the period "New BD's inaugural complete quarter."
Guidance and Segment Performance
BD raised its fiscal 2026 adjusted EPS guidance to a range of $12.62 to $12.72, up from the previous $12.52 to $12.72. The company maintained its revenue forecast, anticipating growth near the upper end of its guidance range. The revised outlook implies fourth-quarter adjusted EPS of $4.03 to $4.13, which would represent a significant year-over-year increase from $3.25 in the same period last year.
Revenue growth was broad-based across all four business segments on a currency-neutral basis. Interventional led with 5.5% growth, followed by BioPharma Systems at 5.2%, Connected Care at 4.4%, and Medical Essentials at 3.2%. Geographically, U.S. revenue rose 6.9% on a currency-neutral basis, while international revenue edged up just 0.6%, highlighting a widening divergence. Advanced Patient Monitoring posted a standout 11.2% growth, while Medication Delivery gained 1.6%.
Cash Flow Dynamics and Capital Allocation
The nine-month cash bridge reveals why the rally may face scrutiny. Free cash flow increased even as adjusted earnings and income from continuing operations declined. Income from continuing operations fell 4.0% to $725 million, while operating cash flow rose 33.3% to $2.104 billion. Capital expenditures were roughly flat at $376 million, and free cash flow per diluted share rose 48.2% to $6.14.
Capital allocation remained aggressive. BD repaid $2.70 billion in debt and repurchased $2.25 billion worth of shares. The company also received a $3.86 billion distribution from the spun-off entity, following the February 9 completion of the merger of its former biosciences and diagnostics units with Waters Corporation (NYSE: WAT). Prior-period results have been restated to reflect continuing operations.
Analyst Sentiment and Risks
FactSet data showed a cautious stance among analysts, with eight of 15 rating BDX as Hold and seven assigning Buy or Overweight. The consensus rating is Overweight, but the median price target of $177.50 and average target of $178.20 are only marginally above the current trading price, suggesting limited upside without revised targets.
Key risks include the reliance on working-capital releases for cash flow growth, sluggish international expansion, and potential headwinds from tariffs, China's volume-based procurement, and the timing of Alaris remediation. The earnings beat provides some reassurance, but a sustained re-rating will depend on consistent cash generation that does not rely on further working-capital improvements.
In after-hours trading, BDX outperformed its peers, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), and Baxter International (BAX).
